NCT05039099
A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 2, 2021
Completion: Aug 13, 2025